WO2006126214A2 - Injectable compositions and process for preparation of such compositions - Google Patents

Injectable compositions and process for preparation of such compositions Download PDF

Info

Publication number
WO2006126214A2
WO2006126214A2 PCT/IN2006/000177 IN2006000177W WO2006126214A2 WO 2006126214 A2 WO2006126214 A2 WO 2006126214A2 IN 2006000177 W IN2006000177 W IN 2006000177W WO 2006126214 A2 WO2006126214 A2 WO 2006126214A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
cox
solution
mixture
inhibitor
Prior art date
Application number
PCT/IN2006/000177
Other languages
French (fr)
Other versions
WO2006126214A3 (en
Inventor
Rajesh Jain
Kour Chand Jindal
Sukhjeet Singh
Sanjay Boldhane
Original Assignee
Panacea Biotec Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to RSP-2007/0461A priority Critical patent/RS20070461A/en
Priority to CA002609242A priority patent/CA2609242A1/en
Priority to AU2006250765A priority patent/AU2006250765A1/en
Priority to EP06756263A priority patent/EP1895983A2/en
Priority to BRPI0611170-0A priority patent/BRPI0611170A2/en
Priority to JP2008513009A priority patent/JP2008542260A/en
Application filed by Panacea Biotec Ltd. filed Critical Panacea Biotec Ltd.
Priority to MX2007014862A priority patent/MX2007014862A/en
Priority to EA200702646A priority patent/EA200702646A1/en
Publication of WO2006126214A2 publication Critical patent/WO2006126214A2/en
Publication of WO2006126214A3 publication Critical patent/WO2006126214A3/en
Priority to NO20076468A priority patent/NO20076468L/en
Priority to TNP2007000482A priority patent/TNSN07482A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to novel and highly stable injectable pharmaceutical compositions comprising at least one cyclooxygenase-II enzyme (COX-II) inhibitor or non-steroidal anti-inflammatory drug (NSAID) or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs or salts thereof as active ingredient suitable for parenteral administration preferably by intramuscular
  • COX-II cyclooxygenase-II enzyme
  • NSAID non-steroidal anti-inflammatory drug
  • COX/LOX inhibitor COX/LOX inhibitor
  • the analgesic and anti-inflammatory injectable compositions of the present invention are very useful in mammals particularly in humans for the treatment of acute painful conditions like one or more of post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurological pain and pain associated with sciatica
  • Non-steroidal anti-inflammatory drugs '(NSAIDs) and cyclooxygenase-II enzyme (COX-Il) ' inhibitors 1 ' are 1 1 i ⁇ l ! - general : highly 1 ⁇ hydrophobic compounds and readily precipitate even 4 in 'the presence 1 bf 'minor amounts of water. Hence it is very difficult to formulate ⁇ such compounds into injectable compositions for intramuscular or intravenous use.
  • NSAIDs such as nimesulide, ketorolac, diclofenac, ibuprofen and naproxen, and COX- II inhibitors" in 'parenteral forrni 1 capable of instant 'therapeutic action are extremely desirable.
  • a suitable', safe 1 and non-toxic carrier/vehicle is required in which these drugs are soluble. Due to the physico-chemical properties of these groups of compounds, the NSAIDs or the COX-II inhibitors are poorly soluble in water hence presenting a difficulty in formulating these drugs in the parenteral fprrn.
  • injectable compositions comprising of NSAIDs such as nimesulide.
  • An injectable formulation of nimesulide has been reported in PCT Patent No. WO 95/34533 that discloses the utilization of a salt form of nimesulide with L-lysine which is in turn further complexed with cyclodextrins that may be dissolved in water to give an injectable preparation.
  • the maximum solubility achieved by this injectable composition was reported to be 2.4 mg/ml, which is not sufficient for intramuscular administration, as it would require very large volumes to administer therapeutic doses.
  • Nimesulide is a potent non-steroidal anti-inflammatory (NSAID) drug, presently used in the treatment of painful inflammatory conditions due to rheumatoid arthritis, which also possesses antipyretic activity. Compared to other NSAIDs, nimesulide has a better therapeutic ratio, low gastro toxicity and generally good tolerability. Nimesulide is a strongly hydrophobic substance that is practically insoluble in water (solubility in water at room temperature being 0.01 mg/ml). Since nimesulide is insoluble in water and in a large number of non-toxic solvents specifically those which are approved for parenteral use, it becomes highly difficult to formulate it into solutions suitable for parenteral administration via intramuscular or intravenous route.
  • NSAID non-steroidal anti-inflammatory
  • NSAIDs such as diclofenac, ibuprofen, indomethacin, and naproxen also offer a lot of difficulty in making them into injectable compositions using approved excipients and the permissible concentrations in which they are approved for parenteral use.
  • Parenteral compositions particularly comprising cyclooxygenase-II inhibitors such as rofecoxib or valdecoxib are highly unstable upon storage due to the tendency of such drugs to precipitate out, and hence it becomes difficult to obtain a homogeneous solution for parenteral administration during the shelf life of such products. It is known and well accepted that parenteral administration of drugs for the treatment of painful inflammatory conditions, is more effective than other routes of administration, since the drug enters the circulation directly and promptly manifests its therapeutic effect.
  • compositions containing propofol suitable for parenteral administration to produce anesthesia in warm-blooded animals as mixtures of propofol with surfactants such as Cremophor® RH40, Cremophor® EL, and Tween® 80 in an aqueous medium that may also contain ethanol or other pharmaceutically acceptable ingredients.
  • surfactants such as Cremophor® RH40, Cremophor® EL, and Tween® 80 in an aqueous medium that may also contain ethanol or other pharmaceutically acceptable ingredients.
  • 4,794, 1 17 claims a process for solubilizing indomethacin in water consisting essentially of dissolving an anti-inflammatory amount of indomethacin in a solubilizing amount of at least one polyethylene glycol having a molecular weight of 300 to 700 and dissolving the resulting solution in a solubilizing amount of an aqueous medium buffered in a pH range of 4.5 to 8 especially intended for the external use.
  • US Patent No. 4,798,846 discloses sterile propofol compositions containing 1% to 2% propofol alone or dissolved in oil such as arachis oil or ethyl oleate. These formulations are stabilized with surfactants.
  • 5,858,999 discloses a sterile aqueous pharmaceutical composition for parenteral administration which comprises about 0.9 to about 90 mg/ml of a lazaroid or a pharmaceutically acceptable salt thereof, about 0.002 to about 2.0M citrate, upto about 80% of a cosolvent selected from the group consisting of propylene glycol, polyethylene glycol, glycerol, ethanol, dimethylsulfoxide, dimethylacetamide, dimethyl isosorbide, N-methyl-2-pyrrolid ⁇ ne and water at a pH of about 2.4 to about 3.5. These compositions use very high concentrations of cosolvents.
  • US Patent No. 5,688,829 assigned to the applicant of the present invention discloses a therapeutic injectable analgesic pharmaceutical composition for intra-muscular administration comprising essentially nimesulide in a parenteral absorption enhancing base comprising dimethyiacelamide, benzyl benzoate and ethyl oleate.
  • the said composition uses lipophilic solvents that are oily in nature to solubilize nimesulide, which does not allow administration of the injectable via the intravenous route.
  • 6,451,302 assigned to the same applicant describes an injectable water- miscible composition
  • nimesulide benzyl alcohol
  • a substance selected from the group consisting of dimethylacctamide, dimethylformamide, dimethylsulphoxide, and N-methyl pyrrolidone and a glycol selected from the group consisting of polyethylene glycol (PEG 200 to 600), propylene glycol, hexylene glycol, butylene glycol, and polyethylene glycol 660 hydroxy stearate.
  • PEG 200 to 600 polyethylene glycol
  • propylene glycol propylene glycol
  • hexylene glycol hexylene glycol
  • butylene glycol butylene glycol
  • polyethylene glycol 660 hydroxy stearate polyethylene glycol
  • US Patent No. 6,589,973 pertains to a clear, stable novel pharmaceutical preparation of selective COX-II inhibitors in the parenteral form for the treatment of pain and inflammatory conditions arising because of cyclooxygenase-II activity.
  • the pharmaceutical preparation of COX-II inhibitors comprise of selective COX-II inhibitors such as celecoxib, rofecoxib and their analogs dissolved in a selective isosorbide type solvent.
  • EP Patent No. 1228757 relates to stable pharmaceutical solutions suitable for parenteral administration of nimesulide consisting of 80% glycerol formal, 15% ethanol and 5% water and/or 75% glycerol formal, 10% ethanol, 10% propylene glycol and 5% water.
  • PCT Publication No. WO 2000072884 describes a novel pharmaceutical composition of nimesulide and 2,5-di-0-methyl-l,4:3,6-dianhydro-D-glucitol with or without water, optionally containing one or more diluents which can be used for IWIM administration or oral or topical formulations.
  • 20030078266 specifically relates to a pharmaceutical composition
  • a pharmaceutical composition comprising in powder form, at least one water-soluble therapeutic agent selected from selective COX-2 inhibitory drugs and prodrugs and salts thereof, in a therapeutically effective total amount constituting about 30% to about 90% by weight, a parenterally acceptable buffering agent in an amount of about 5% to about 60% by weight, and other parenterally acceptable excipient ingredients in a total amount of zero to about 10% by weight, of the composition; said composition being reconstitutable in a parenterally acceptable solvent liquid to form an injectable solution.
  • compositions intended for parenteral use should be nontoxic and should be preferably present in low concentrations.
  • Most of the existing patent and literature references describe parenteral compositions, which comprise very high concentrations of solvents that are primarily not approved for parenteral use and also are unstable during storage.
  • compositions comprising COX-II inhibitors or NSAIDs in which the latter are substantially soluble, and compositions those are devoid of such aforementioned problems and which could remain stable throughout the shelf life of the product.
  • the inventors of the present invention have done extensive research and conducted several experiments using different non-toxic solvents and discovered that their combination in various concentrations along with suitable buffers and alkalizing agents results in a highly solubilized system suitable for parenteral administration in which the COX-II inhibitors and/or NSAIDs are soluble and which are also stable during the storage of the product thus demonstrating a significant advancement over the prior art.
  • It is an objective of the present invention to provide novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system comprising "a mixture of glycols; optionally with other pharmaceutically acceptable excipients.
  • It is an objective of the present invention to provide novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient; a solvent system comprising a mixture of glycols; at least one alkalizing agent; optionally with other pharmaceutically acceptable excipients.
  • It is an objective of the present invention to provide novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient; a solvent system comprising a mixture of glycols; at least one alkalizing agent; at least one buffering agent; optionally with other pharmaceutically acceptable excipients.
  • compositions comprising a NSAID preferably nimesulide as active ingredient, a solvent system comprising a mixture of glycols, at least one alkalizing agent, at least one buffering agent, optionally with other pharmaceutically acceptable excipients.
  • It is another objective of the present invention to provide novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system comprising a mixture of glycols; optionally with other pharmaceutically acceptable excipients, additionally comprising one or more other pharmaceutically acceptable active ingredient(s).
  • IM intramuscular
  • IV intravenous
  • It is yet another objective of the present invention to provide a process for preparation of a novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system comprising a mixture of glycols; optionally with other pharmaceutically acceptable excipients, which comprises of the following steps: i) adding the active ingredient(s) to the mixture of glycols followed by mixing, ii) optionally adding other pharmaceutically acceptable excipients and mixing to produce the injectable composition.
  • It is a still further objective of the present invention to provide a process for preparation of a novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system comprising a mixture of glycols; optionally with other pharmaceutically acceptable excipients, additionally comprising one or more buffering agent(s) and/or alkalizing agent(s), which comprises of the following steps: i) adding one or more buffering agent(s) to the mixture of glycols and mixing to obtain a homogeneous mixture, ii) adding the active ingredient(s) to the mixture followed by mixing, iii) adding alkalizing agent(s) followed by mixing, iv) adding the buffering agent(s) with mixing to obtain a homogeneous mixture, v) optionally adjusting the pH of the mixture to an alkaline pH by adding al
  • compositions of the present invention are particularly useful for the treatment of one or more acute painful conditions such as post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurological pain and pain associated with sciatica and spondylitis, or chronic painful conditions, and/or other associated disorders.
  • acute painful conditions such as post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurological pain and pain associated with sciatica and spondylitis, or chronic painful conditions, and/or other associated disorders.
  • the present invention describes novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient.
  • the active ingredient is a NSAID, more preferably nimesulide.
  • the compositions of the present invention additionally comprise a solvent system comprising a mixture of glycols, optionally with other pharmaceutically acceptable excipients.
  • novel injectable pharmaceutical compositions of the present invention comprise additionally at least one alkalizing agent(s) and/or at least one buffering agent(s).
  • the novel injectable pharmaceutical composition comprises at least one COX-II inhibitor or NSAID or COX/LOX inhibitor or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts or thereof as active ingredient from about 0.1% to about 80% w/v of the composition and a solvent system comprising a mixture of glycols from about 1% to about 80% v/v of the composition; optionally with other pharmaceutically acceptable excipients.
  • the composition of the present invention additionally comprise at least one alkalizing agent from about 0.2% to about 60% v/v of the composition and/or at least one buffering agent from about 2% to about 80% v/v of the composition.
  • the present invention provides novel injectable pharmaceutical compositions comprising nimesulide as active ingredient, a solvent system comprising a mixture of glycols, at least one alkalizing agent, at least one buffering agent, optionally with other pharmaceutically acceptable excipients.
  • the injectable compositions comprising COX-II inhibitor or NSAID or COX/LOX inhibitor can be prepared using a mixture of different non-toxic solvents in various concentrations along with suitable buffers and alkalizing agents. These compositions are clear, odorless, highly stable, non-toxic and homogeneous and are therefore suitable for parenteral administration.
  • the injectable compositions are suitable particularly for administration by intravenous (IV) or intramuscular (IM) route.
  • the solubilization techniques used to solubilize the poorly soluble COX-II inhibitors or NSAIDs or COX/LOX inhibitor are based on cosolvation and/or pH modification techniques.
  • the compositions of the present invention are highly stable, preferably in the pH range of about 7.5 to 1 1.5, more preferably in the pH range of about 9.0 to 1 1.0.
  • the active ingredient useful in the present invention are preferably NSAIDs selected from but not limited to a group comprising nimesulide, nabumetone, tapoxalin, diclofenac, flosulide ibuprofen, indomethacin, naproxen, and the like, their tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof or COX-II inhibitors selected from but not limited to a group comprising celecoxib, rofecoxib, valdecoxib, etoricoxib, parecoxib, itacoxib, deracoxib and the like or their tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs or salts thereof.
  • NSAIDs selected from but not limited to a group comprising nimesulide, nabumetone, tapoxalin, diclofenac, flosulide
  • the active ingredient of the present invention belongs to the category of COX/LOX (cyclooxygenase/lipooxygenase) inhibitor such as licofelone.
  • the active ingredient is present in the micronized form.
  • the novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system comprising a mixture of glycols; optionally with other pharmaceutically acceptable excipients, additionally comprises one or more other pharmaceutically acceptable active ingredient(s).
  • compositions useful in the present invention is any active agent, which can be combined with a COX-II inhibitor or a NSAID or COX/LOX inhibitor, known in the art such as acetaminophen, serratiopeptidase, antibacterial agents, CNS agents, CVS agents, or the like.
  • the mixture of glycols used to make the solvent system is polyethylene glycol (PEG) selected from but not limited to a group comprising PEG 200, PEG 300, PEG 400, PEG 600 and PEG 700, or mixtures thereof; and propylene glycol.
  • the solvent system comprises a mixture of PEG 400 and propylene glycol.
  • the alkalizing agent used is an inorganic base or an organic base or a combination of both.
  • the alkalizing agent used is selected from but not limited to a group comprising inorganic bases such as sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, calcium carbonate, magnesium carbonate, magnesium oxide, and the like, or mixtures thereof; and/or organic bases such as meglumine, triethanolamine, diethanolamine and the like, or mixtures thereof.
  • the alkalizing agent is an inorganic base such as sodium hydroxide or potassium hydroxide.
  • the alkalizing agent is preferably used as an aqueous (water) solution, prepared by dissolving the said agent in water. The quantity of the said agent and volume of water in which the agent is dissolved is used so as to obtain desired concentration of the agent.
  • the buffering agent used in the present invention is preferably an alkaline buffering agent selected from but not limited to a group comprising glycine buffer, lysine buffer, phosphate buffer, acetate buffer, and the like, or mixtures thereof, preferably having a pH range of about 7.2 to about 12.5.
  • glycine buffer is used as the buffering agent in the -compositions of the present invention.
  • glycine buffer having pH of about 8.3 to about 1 1.3 is used as the buffering agent.
  • the buffering agent is preferably used as an aqueous (water) solution, prepared by dissolving the desired compound(s) in water. The quantity of the desired compound(s) and volume of water in which the desired compound(s) is dissolved is used so as to obtain desired concentration and pH of the agent.
  • compositions ofthe present invention are selected from but not limited to the group of excipients generally known to persons skilled in the art e.g. vehicles, bulking agents, stabilizers, preservatives, surfactants, hydrophilic polymers, solubility enhancing agents such as glycerine, various grades of polyethylene oxides, beta-cyclodextrihs like sulfobutylether-beta-cyclodextrin, transcutol and glycofurol, tonicity adjusting agents, local anesthetics, pH adjusting agents, antioxidants, osmotic agents, chelating agents, viscosifying agents, wetting agents, emulsifying agents, acids, sugar alcohol, reducing sugars, non-reducing sugars and the like, or mixtures thereof.
  • the Pharmaceutically acceptable excipient(s) is used in an amount of about 0.1% to about 70% w/v or v/v of the composition.
  • the vehicles suitable useful in the present invention can be selected from but not limited to a group comprising dimethylacetamide, dimethylformamide, dimethylsulphoxide, N-methyl pyrrolidone, benzyl benzoate, benzyl alcohol, ethyl oleate, polyoxyethylene glycolated castor oils (Cremophor® EL), polyethylene glycol such as those having molecular weight of about 200 to 6000, propylene glycol, hexylene glycols, butylene glycols and glycol derivatives such as polyethylene glycol 660 hydroxy stearate (Solutrol® HS 15) and the like, or mixtures thereof.
  • a group comprising dimethylacetamide, dimethylformamide, dimethylsulphoxide, N-methyl pyrrolidone, benzyl benzoate, benzyl alcohol, ethyl oleate, polyoxyethylene glycolated castor oils (Cremophor® EL), polyethylene glycol such
  • the compositions additionally comprises an antimicrobial preservative such as benzyl alcohol preferably at a concentration of about 0.001% to about 5.0% w/w of the composition.
  • an antimicrobial preservative such as benzyl alcohol preferably at a concentration of about 0.001% to about 5.0% w/w of the composition.
  • the composition additionally comprises a conventionally known antioxidant selected from but not limited to a group comprising ascorbyl palmitate, butyl hydroxy anisole, butyl hydroxy toluene, propyl gal late, ⁇ -tocopherol and the like, or mixtures thereof.
  • a conventionally known antioxidant selected from but not limited to a group comprising ascorbyl palmitate, butyl hydroxy anisole, butyl hydroxy toluene, propyl gal late, ⁇ -tocopherol and the like, or mixtures thereof.
  • compositions of the present invention are highly stable.
  • the novel compositions of the present invention may be diluted with suitable diluting fluids known to the art to prepare a solution or ' dispersion or infusion before administration.
  • suitable diluting fluids known to the art to prepare a solution or ' dispersion or infusion before administration.
  • the novel compositions of the present invention are highly stable and compatible with different diluting fluids such as demineralized (DM) water, dextrose 5% w/v, sodium chloride 0.9% w/v or mixtures thereof. These fluids can be employed during the manufacture of the composition or can be used for diluting the composition before administration.
  • DM demineralized
  • the composition is stable for 5 hrs upto 1 : 150 dilution and for 48 hrs up to 1 :5 dilution with DM water; for 2 hrs upto 1 : 150 dilution and for 4 hrs upto 1 :3 dilution with dextrose 5.0% solution; and for 24 hrs upto 1 : 150 dilution and for 48 hrs upto 1 : 100 dilution with 0.9% NaCl solution, particularly at room temperature.
  • compositions of the present invention are preferably filled into ampoules.
  • Compatibility study on nimesulide injection (content of one ampoule) with different infusion solutions were performed to study the physical stability (during intravenous infusion) of the injection after diluting with infusion solutions.
  • Most of the infusion solutions possess pH in acidic range (e.g. Normal saline, about 6.2; Ringer lactate solution, about 6.5 and Dextrose 5% w/v, about 5.5).
  • Admixing with infusion solution for known injections comprising a COX-II inhibitor or NSAID or COX/LOX inhibitor results into saturation and thus crystallization. This is not desirable for a solution if diluted as such since such solution is meant for parenteral administration.
  • ethanol and/or dimethylacetamide (DMA) can also be added to the compositions of the present invention to further enhance the solubility of the active ingredient(s).
  • Example- 1 Stability study was conducted on the composition stated in Example- 1 herein. Long term (at controlled room temperature i.e. 25°C), intermediate (at 30 0 C and 70% RH), accelerated (at 40 0 C and 75% RH), and stress (at 60 0 C) stability studies were performed on the product and samples were analyzed including the controlled samples kept at freezing conditions (at 2-8 0 C). The product was found to be stable for more than six months at each of the above conditions and it did not show any stability issues relating to physical changes like particulate matter, crystallization and color change or chemical changes such as change in potency or presence of any degradation product.
  • the nimesulide injection is formulated preferably as an aqueous injection meant for dilution with infusion solutions particularly in case of IV administration.
  • Nimesulide possess pH dependent solubility i.e. nimesulide is soluble at alkaline pH and practically insoluble at acidic pH.
  • a solvent system comprising a mixture of solvents (particularly glycols) optionally along with a pH adjusting system has been adopted to prepare a stable formulation in the present invention.
  • Nimesulide IM injection Label claim: Each 3 ml contains 100 mg of nimesulide
  • No toxicity symptoms were observed at dose level of 41.6 mg/kg of nimesulide injection and with 2.5 ml/kg placebo injection in mice.
  • Mice injected with a dose of 83.3, 166.67, 208.33 or 250 mg/kg showed toxicity symptoms.
  • the " mortality rates of 40%, 80%, and 100% were observed at dose level of 166.67 mg/kg, 208.33 mg/kg, and 250 mg/kg respectively.
  • the LD 50 of the nimesulide injection when administered intramuscularly was found to be 173.78 mg/kg.
  • Nimesulide IV injection of the present invention when tested (at blood to test sample ratio of 1 : 10) on Rat packed red blood cells (citrated) showed comparative fractions of healthy cells as compared to CALMPOSE®, FORTWIN®, NIMOVET® and VOVERAN®.
  • the perivenous tolerance following a single intravenous administration of Nimesulide IV injection 100 mg/3 ml of the present invention against a placebo composition was studied in rabbits. The study showed that the animals injected intravenously with Nimesulide IV injection of the present invention or the placebo did not show any signs of local irritation at the site of injection in the right ears.
  • Nimesulide IV injection of the present invention was carried out in rabbits.
  • Nimesulide IV injection each 2 ml ampoule containing 75 mg nimesulide, was used.
  • a dose of 3.75 mg/kg body weight of rabbit equivalent to human dose of 75 mg/60kg were administered by IV route , via marginal ear vein of rabbits and blood sampling was done at 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hour intervals, and the plasma samples were analyzed for nimesulide by LC-MS/MS.
  • Table-l Pharmacokinetic profile of Nimesulide injection in rabbits
  • the process for preparation of a novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system comprising a mixture of glycols; optionally with other pharmaceutically acceptable excipients, which comprises of the following steps: i) adding the active ingredient(s) to the mixture of glycols followed by mixing, ii) optionally adding other pharmaceutically acceptable excipients and mixing to produce the injectable composition.
  • the process for preparation of a novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor and/or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system comprising a mixture of glycols; optionally with other pharmaceutically acceptable excipients, additionally comprising one or more buffering agent(s) and/or alkalizing agent(s), which comprises of the following steps: i) adding one or more buffering agent(s) to the mixture of glycols and mixing to obtain a homogeneous mixture, ii) adding the active ingredient(s) to the mixture followed by mixing, iii) adding alkalizing agent(s) followed by mixing, iv) adding the buffering agent(s) with mixing to obtain a homogeneous mixture, v) optionally adjusting the pH of the mixture to an alkaline pH by adding alkalizing agent(s) to produce the
  • the process as described herein comprises the active ingredient selected from a group comprising of at least one COX-II inhibitor or NSAID or
  • COX/LOX inhibitor or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof, optionally with one or more additional active ingredient(s) that can be combined with a COX-II inhibitor or NSAID known to art.
  • a COX-II inhibitor or NSAID known to art.
  • NSAID is nimesulide or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof.
  • compositions of the present invention are provided.
  • the analgesic and anti-inflammatory injectable compositions of the present invention are useful for the treatment of acute painful conditions like post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurological pain and pain associated with sciatica and spondylitis, and the like, in mammals particularly in humans and animals, more particularly in humans.
  • the present invention provides a method of using the novel injectable pharmaceutical composition, which comprises administering to a patient in need thereof an effective amount of the composition.
  • the present invention provides a method of using the injectable pharmaceutical composition preferably for the treatment of acute and/or chronic painful conditions in mammals particularly mammals, including a variety of painful and inflammatory conditions like postoperative pain, primary dysmenorrhea and painful osteoarthritisand/or other associated disorders such as inflammation, fever, allergy, or the like.
  • the present invention provides a method of using the injectable pharmaceutical composition particularly for the treatment of acute painful conditions, wherein such condition is one or more of post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurological pain and pain associated with sciatica and spondylitis.
  • the use of the compositions of the present invention for the preparation of medicament for the treatment of acute painful conditions wherein such condition is one or more of post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurological pain and pain associated with sciatica and spondylitis, and/or chronic painful conditions, and/or painful and inflammatory conditions like postoperative pain, primary dysmenorrhea and painful osteoarthritis and/or other associated disorders such as inflammation, fever, allergy, or the like.
  • Example-1 Nimesulide Injection (100 mg/3 ml)
  • Example-2 Diclofenac Injection (75 mg/3 ml)
  • Example-9 Nimesulide Injection (100 mg/3 ml)
  • Nimesulide 3.34 gm 5 Potassium hydroxide (KOH) solution 5.6 % w/v 1 1 .20 ml
  • Procedure i) Take specified quantity (20.00 ml) of PEG-600 into a vessel. iJX Add Propylene glycol (10.00 ml) to step (i) with continuous stirring. iii) Add about 50.0 ml of the Phosphate Buffer pH 7.2 to the step (ii) with continuous stirring to form a homogeneous mixture, iv) Add weighed amount of Nimesulide (3.34 gm) passed through #60 mesh to the step (iii) with continuous stirring.
  • Example-10 Nimesulide Injection (100 mg/3 ml)
  • Example-12 Licofelone injection (100 mg/3 ml):
  • Example-13 Parecoxib injection (50 mg/2 ml):
  • Example-14 Diclofenac Sodium injection (75 nig/2 ml):
  • Example-15 Ibuprofen injection (200 mg/2 ml):

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Novel and highly stable injectable pharmaceutical compositions comprising at least one cyclooxygenase-II enzyme (COX-II) inhibitor or non-steroidal anti-inflammatory drug (NSAID) or .COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs or salts thereof as active ingredient suitable for parenteral administration preferably by intramuscular (IM) or intravenous (IV) route; process of preparing such compositions and therapeutic methods of using such compositions are provided. The analgesic and anti-inflammatory injectable compositions of the present invention are very useful in mammals particularly in humans for the treatment of acute painful conditions like one or more of post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurological pain and pain associated with sciatica and spondylitis, and the like, and/or chronic painful conditions, and/or a variety of painful and inflammatory conditions like postoperative pain, primary dysmenorrhea and painful osteoarthritis, and/or other associated disorders such as inflammation, fever, allergy, or the like.

Description

NOVEL INJECTABLE COMPOSITIONS AND PROCESS OF PREPARATION
THEREOF
FIELD OF THE INVENTION
The present invention relates to novel and highly stable injectable pharmaceutical compositions comprising at least one cyclooxygenase-II enzyme (COX-II) inhibitor or non-steroidal anti-inflammatory drug (NSAID) or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs or salts thereof as active ingredient suitable for parenteral administration preferably by intramuscular
(DVT)Or- intravenous (IV) route; process of preparing such compositions and therapeutic methods of using such compositions.
The analgesic and anti-inflammatory injectable compositions of the present invention are very useful in mammals particularly in humans for the treatment of acute painful conditions like one or more of post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurological pain and pain associated with sciatica
, i ' ' M i l i i ' l . i • • ' . ■ i n i . ; I ' i i i - i i h and spondylitis, and the like, and/or chronic painful conditions, and/or other associated
! ι | ' . i . ϊ 1 1 >. ■ . : i M , . , I K i l l ' ■ , , , . i ' I |( I . , . -i v ' l kl ' i . I l disorders such as inflammation, fever, allergy, or the like.
BACKGROUND OF THE INVENTION Non-steroidal anti-inflammatory drugs '(NSAIDs) and cyclooxygenase-II enzyme (COX-Il) ' inhibitors1 ' are1 1 iήl !- general : highly1 κ hydrophobic compounds and readily precipitate even4 in 'the presence1 bf 'minor amounts of water. Hence it is very difficult to formulate \ such compounds into injectable compositions for intramuscular or intravenous use.
■ ■ i
NSAIDs such as nimesulide, ketorolac, diclofenac, ibuprofen and naproxen, and COX- II inhibitors" in 'parenteral forrni1 capable of instant 'therapeutic action are extremely desirable. In1 order' to1 prepare parenteral formulations of these classes of compounds, a suitable', safe1 and non-toxic carrier/vehicle (is required in which these drugs are soluble. Due to the physico-chemical properties of these groups of compounds, the NSAIDs or the COX-II inhibitors are poorly soluble in water hence presenting a difficulty in formulating these drugs in the parenteral fprrn. Attempts to provide NSAIDs and COX- Il inhibitory drugs or their analogs in parenteral lorm using various solvents such as alcohols, dimethyl sulphoxide, propylene glycol and glycerin were found to be unsuccessful either due to problems of solubility or that when these drugs dissolve in solvents like isopropenol acid mixture, dimethyl sulphoxide and propylene glycol, the desired concentration range for the therapeutic administration of the above drugs particularly through intramuscular route does not permit the above solvent usage as they are found to be toxic. Due to such .problems, it has been extremely difficult to develop stable injectable formulation of such drugs.
Several efforts have been made in the past to make injectable compositions comprising of NSAIDs such as nimesulide. An injectable formulation of nimesulide has been reported in PCT Patent No. WO 95/34533 that discloses the utilization of a salt form of nimesulide with L-lysine which is in turn further complexed with cyclodextrins that may be dissolved in water to give an injectable preparation. The maximum solubility achieved by this injectable composition was reported to be 2.4 mg/ml, which is not sufficient for intramuscular administration, as it would require very large volumes to administer therapeutic doses. Moreover, making a salt form of nimesulide and then combining with cyclodextrins not only makes the process cumbersome but also increases the cost of the formulations. Another reference (Daffonehio, L. et al.,
Inflammatory Research, 45, 259-264, 1995), wherein nimesulide is dissolved in saline for intravenous administration for experimental studies in animals, also describes only very dilute solutions which cannot deliver therapeutic doses of nimesulide in humans.
Nimesulide is a potent non-steroidal anti-inflammatory (NSAID) drug, presently used in the treatment of painful inflammatory conditions due to rheumatoid arthritis, which also possesses antipyretic activity. Compared to other NSAIDs, nimesulide has a better therapeutic ratio, low gastro toxicity and generally good tolerability. Nimesulide is a strongly hydrophobic substance that is practically insoluble in water (solubility in water at room temperature being 0.01 mg/ml). Since nimesulide is insoluble in water and in a large number of non-toxic solvents specifically those which are approved for parenteral use, it becomes highly difficult to formulate it into solutions suitable for parenteral administration via intramuscular or intravenous route. Other NSAIDs such as diclofenac, ibuprofen, indomethacin, and naproxen also offer a lot of difficulty in making them into injectable compositions using approved excipients and the permissible concentrations in which they are approved for parenteral use. Parenteral compositions particularly comprising cyclooxygenase-II inhibitors such as rofecoxib or valdecoxib are highly unstable upon storage due to the tendency of such drugs to precipitate out, and hence it becomes difficult to obtain a homogeneous solution for parenteral administration during the shelf life of such products. It is known and well accepted that parenteral administration of drugs for the treatment of painful inflammatory conditions, is more effective than other routes of administration, since the drug enters the circulation directly and promptly manifests its therapeutic effect.
Seedher, Neelam et. al. (Indian Journal of Pharmaceutical Sciences, 65(1), 58-61 , 2003) had described the solubility of nimesulide in various solvents and solvent-cosolvent mixtures in relation to the development of parenteral formulations. The said publication showed that the solubilization of nimesulide increased in semi-polar solvents such as polyethylene glycols (PEGs) and non-ionic surfactants such as Tween® 80 and Brij® 30. However, the concentration of PEGs used to achieve the desired solubility is too high i.e. 90% which is not recommended for parenteral use specifically meant for IV administration. US Patent Nos. 4,056,635 and 4,452,817 disclose compositions containing propofol suitable for parenteral administration to produce anesthesia in warm-blooded animals as mixtures of propofol with surfactants such as Cremophor® RH40, Cremophor® EL, and Tween® 80 in an aqueous medium that may also contain ethanol or other pharmaceutically acceptable ingredients. US Patent No. 4,794, 1 17 claims a process for solubilizing indomethacin in water consisting essentially of dissolving an anti-inflammatory amount of indomethacin in a solubilizing amount of at least one polyethylene glycol having a molecular weight of 300 to 700 and dissolving the resulting solution in a solubilizing amount of an aqueous medium buffered in a pH range of 4.5 to 8 especially intended for the external use. US Patent No. 4,798,846 discloses sterile propofol compositions containing 1% to 2% propofol alone or dissolved in oil such as arachis oil or ethyl oleate. These formulations are stabilized with surfactants. US Patent No. 5,858,999 discloses a sterile aqueous pharmaceutical composition for parenteral administration which comprises about 0.9 to about 90 mg/ml of a lazaroid or a pharmaceutically acceptable salt thereof, about 0.002 to about 2.0M citrate, upto about 80% of a cosolvent selected from the group consisting of propylene glycol, polyethylene glycol, glycerol, ethanol, dimethylsulfoxide, dimethylacetamide, dimethyl isosorbide, N-methyl-2-pyrrolidόne and water at a pH of about 2.4 to about 3.5. These compositions use very high concentrations of cosolvents.
US Patent No. 5,688,829 assigned to the applicant of the present invention discloses a therapeutic injectable analgesic pharmaceutical composition for intra-muscular administration comprising essentially nimesulide in a parenteral absorption enhancing base comprising dimethyiacelamide, benzyl benzoate and ethyl oleate. The said composition uses lipophilic solvents that are oily in nature to solubilize nimesulide, which does not allow administration of the injectable via the intravenous route. Another US Patent No. 6,451,302 assigned to the same applicant describes an injectable water- miscible composition comprising nimesulide; benzyl alcohol; a substance selected from the group consisting of dimethylacctamide, dimethylformamide, dimethylsulphoxide, and N-methyl pyrrolidone; and a glycol selected from the group consisting of polyethylene glycol (PEG 200 to 600), propylene glycol, hexylene glycol, butylene glycol, and polyethylene glycol 660 hydroxy stearate. The said patent necessitates the use of alkyl amides/alkyl sulphoxides or pyrrolidones to solubilize nimesulide.
US Patent No. 6,589,973 pertains to a clear, stable novel pharmaceutical preparation of selective COX-II inhibitors in the parenteral form for the treatment of pain and inflammatory conditions arising because of cyclooxygenase-II activity. In particular, the pharmaceutical preparation of COX-II inhibitors comprise of selective COX-II inhibitors such as celecoxib, rofecoxib and their analogs dissolved in a selective isosorbide type solvent. EP Patent No. 1228757 relates to stable pharmaceutical solutions suitable for parenteral administration of nimesulide consisting of 80% glycerol formal, 15% ethanol and 5% water and/or 75% glycerol formal, 10% ethanol, 10% propylene glycol and 5% water. However the solvents and the concentrations in which they are used are not approved for parenteral administration. PCT Publication No. WO 2000072884 describes a novel pharmaceutical composition of nimesulide and 2,5-di-0-methyl-l,4:3,6-dianhydro-D-glucitol with or without water, optionally containing one or more diluents which can be used for IWIM administration or oral or topical formulations. US Publication No. 20030078266 specifically relates to a pharmaceutical composition comprising in powder form, at least one water-soluble therapeutic agent selected from selective COX-2 inhibitory drugs and prodrugs and salts thereof, in a therapeutically effective total amount constituting about 30% to about 90% by weight, a parenterally acceptable buffering agent in an amount of about 5% to about 60% by weight, and other parenterally acceptable excipient ingredients in a total amount of zero to about 10% by weight, of the composition; said composition being reconstitutable in a parenterally acceptable solvent liquid to form an injectable solution.
The solvents used to formulate compositions intended for parenteral use should be nontoxic and should be preferably present in low concentrations. Most of the existing patent and literature references describe parenteral compositions, which comprise very high concentrations of solvents that are primarily not approved for parenteral use and also are unstable during storage.
Hence, there still exists an unmet need for developing effective non-toxic parenteral compositions comprising COX-II inhibitors or NSAIDs in which the latter are substantially soluble, and compositions those are devoid of such aforementioned problems and which could remain stable throughout the shelf life of the product.
The inventors of the present invention have done extensive research and conducted several experiments using different non-toxic solvents and discovered that their combination in various concentrations along with suitable buffers and alkalizing agents results in a highly solubilized system suitable for parenteral administration in which the COX-II inhibitors and/or NSAIDs are soluble and which are also stable during the storage of the product thus demonstrating a significant advancement over the prior art.
SUMMARY OF THE INVENTION
It is an objective of the present invention to provide novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system comprising "a mixture of glycols; optionally with other pharmaceutically acceptable excipients.
It is an objective of the present invention to provide novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient; a solvent system comprising a mixture of glycols; at least one alkalizing agent; optionally with other pharmaceutically acceptable excipients.
It is an objective of the present invention to provide novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient; a solvent system comprising a mixture of glycols; at least one alkalizing agent; at least one buffering agent; optionally with other pharmaceutically acceptable excipients.
It is also an objective of the present invention to provide novel injectable pharmaceutical compositions comprising a NSAID preferably nimesulide as active ingredient, a solvent system comprising a mixture of glycols, at least one alkalizing agent, at least one buffering agent, optionally with other pharmaceutically acceptable excipients.
It is another objective of the present invention to provide novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system comprising a mixture of glycols; optionally with other pharmaceutically acceptable excipients, additionally comprising one or more other pharmaceutically acceptable active ingredient(s).
It is another objective of the present invention to provide highly stable injectable pharmaceutical compositions suitable for intramuscular (IM) or intravenous (IV) administration.
It is yet another objective of the present invention to provide a process for the preparation of such novel injectable compositions.
It is yet another objective of the present invention to provide a process for preparation of a novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system comprising a mixture of glycols; optionally with other pharmaceutically acceptable excipients, which comprises of the following steps: i) adding the active ingredient(s) to the mixture of glycols followed by mixing, ii) optionally adding other pharmaceutically acceptable excipients and mixing to produce the injectable composition.
It is a still further objective of the present invention to provide a process for preparation of a novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system comprising a mixture of glycols; optionally with other pharmaceutically acceptable excipients, additionally comprising one or more buffering agent(s) and/or alkalizing agent(s), which comprises of the following steps: i) adding one or more buffering agent(s) to the mixture of glycols and mixing to obtain a homogeneous mixture, ii) adding the active ingredient(s) to the mixture followed by mixing, iii) adding alkalizing agent(s) followed by mixing, iv) adding the buffering agent(s) with mixing to obtain a homogeneous mixture, v) optionally adjusting the pH of the mixture to an alkaline pH by adding alkalizing agent(s) to produce the injectable composition.
It is yet another objective of the present invention to provide a method of using such composition which comprises administering to a patient in need thereof an effective amount of the composition.
The compositions of the present invention are particularly useful for the treatment of one or more acute painful conditions such as post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurological pain and pain associated with sciatica and spondylitis, or chronic painful conditions, and/or other associated disorders.
DETAILED DESCRIPTION OF THE INVENTION
The present invention describes novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient. Preferably the active ingredient is a NSAID, more preferably nimesulide. The compositions of the present invention additionally comprise a solvent system comprising a mixture of glycols, optionally with other pharmaceutically acceptable excipients.
In an embodiment, the novel injectable pharmaceutical compositions of the present invention comprise additionally at least one alkalizing agent(s) and/or at least one buffering agent(s).
In an embodiment, the novel injectable pharmaceutical composition comprises at least one COX-II inhibitor or NSAID or COX/LOX inhibitor or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts or thereof as active ingredient from about 0.1% to about 80% w/v of the composition and a solvent system comprising a mixture of glycols from about 1% to about 80% v/v of the composition; optionally with other pharmaceutically acceptable excipients. In another embodiment, the composition of the present invention additionally comprise at least one alkalizing agent from about 0.2% to about 60% v/v of the composition and/or at least one buffering agent from about 2% to about 80% v/v of the composition.
In an embodiment, the present invention provides novel injectable pharmaceutical compositions comprising nimesulide as active ingredient, a solvent system comprising a mixture of glycols, at least one alkalizing agent, at least one buffering agent, optionally with other pharmaceutically acceptable excipients.
According to an embodiment of the present invention, the injectable compositions comprising COX-II inhibitor or NSAID or COX/LOX inhibitor can be prepared using a mixture of different non-toxic solvents in various concentrations along with suitable buffers and alkalizing agents. These compositions are clear, odorless, highly stable, non-toxic and homogeneous and are therefore suitable for parenteral administration. In an embodiment of the present invention, the injectable compositions are suitable particularly for administration by intravenous (IV) or intramuscular (IM) route. In the present invention, the solubilization techniques used to solubilize the poorly soluble COX-II inhibitors or NSAIDs or COX/LOX inhibitor are based on cosolvation and/or pH modification techniques. Particularly, the compositions of the present invention are highly stable, preferably in the pH range of about 7.5 to 1 1.5, more preferably in the pH range of about 9.0 to 1 1.0.
The active ingredient useful in the present invention are preferably NSAIDs selected from but not limited to a group comprising nimesulide, nabumetone, tapoxalin, diclofenac, flosulide ibuprofen, indomethacin, naproxen, and the like, their tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof or COX-II inhibitors selected from but not limited to a group comprising celecoxib, rofecoxib, valdecoxib, etoricoxib, parecoxib, itacoxib, deracoxib and the like or their tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs or salts thereof. In an embodiment, the active ingredient of the present invention belongs to the category of COX/LOX (cyclooxygenase/lipooxygenase) inhibitor such as licofelone. In an embodiment of the present invention, the active ingredient is present in the micronized form.
In an embodiment of the present invention, the novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system comprising a mixture of glycols; optionally with other pharmaceutically acceptable excipients, additionally comprises one or more other pharmaceutically acceptable active ingredient(s). Other pharmaceutically acceptable active ingredient(s) useful in the present invention is any active agent, which can be combined with a COX-II inhibitor or a NSAID or COX/LOX inhibitor, known in the art such as acetaminophen, serratiopeptidase, antibacterial agents, CNS agents, CVS agents, or the like.
In an embodiment of the present invention, the mixture of glycols used to make the solvent system is polyethylene glycol (PEG) selected from but not limited to a group comprising PEG 200, PEG 300, PEG 400, PEG 600 and PEG 700, or mixtures thereof; and propylene glycol. In a preferred embodiment, the solvent system comprises a mixture of PEG 400 and propylene glycol. In an embodiment of the present invention, the alkalizing agent used is an inorganic base or an organic base or a combination of both. In an embodiment of the present invention, the alkalizing agent used is selected from but not limited to a group comprising inorganic bases such as sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, calcium carbonate, magnesium carbonate, magnesium oxide, and the like, or mixtures thereof; and/or organic bases such as meglumine, triethanolamine, diethanolamine and the like, or mixtures thereof. In a preferred embodiment, the alkalizing agent is an inorganic base such as sodium hydroxide or potassium hydroxide. The alkalizing agent is preferably used as an aqueous (water) solution, prepared by dissolving the said agent in water. The quantity of the said agent and volume of water in which the agent is dissolved is used so as to obtain desired concentration of the agent.
The buffering agent used in the present invention is preferably an alkaline buffering agent selected from but not limited to a group comprising glycine buffer, lysine buffer, phosphate buffer, acetate buffer, and the like, or mixtures thereof, preferably having a pH range of about 7.2 to about 12.5. In a preferred embodiment, glycine buffer is used as the buffering agent in the -compositions of the present invention. In a still preferred embodiment, glycine buffer having pH of about 8.3 to about 1 1.3 is used as the buffering agent. The buffering agent is preferably used as an aqueous (water) solution, prepared by dissolving the desired compound(s) in water. The quantity of the desired compound(s) and volume of water in which the desired compound(s) is dissolved is used so as to obtain desired concentration and pH of the agent.
Pharmaceutically acceptable excipients used in the composition ofthe present invention are selected from but not limited to the group of excipients generally known to persons skilled in the art e.g. vehicles, bulking agents, stabilizers, preservatives, surfactants, hydrophilic polymers, solubility enhancing agents such as glycerine, various grades of polyethylene oxides, beta-cyclodextrihs like sulfobutylether-beta-cyclodextrin, transcutol and glycofurol, tonicity adjusting agents, local anesthetics, pH adjusting agents, antioxidants, osmotic agents, chelating agents, viscosifying agents, wetting agents, emulsifying agents, acids, sugar alcohol, reducing sugars, non-reducing sugars and the like, or mixtures thereof. In an embodiment, the Pharmaceutically acceptable excipient(s) is used in an amount of about 0.1% to about 70% w/v or v/v of the composition.
The vehicles suitable useful in the present invention can be selected from but not limited to a group comprising dimethylacetamide, dimethylformamide, dimethylsulphoxide, N-methyl pyrrolidone, benzyl benzoate, benzyl alcohol, ethyl oleate, polyoxyethylene glycolated castor oils (Cremophor® EL), polyethylene glycol such as those having molecular weight of about 200 to 6000, propylene glycol, hexylene glycols, butylene glycols and glycol derivatives such as polyethylene glycol 660 hydroxy stearate (Solutrol® HS 15) and the like, or mixtures thereof.
In another embodiment of the present invention, the compositions additionally comprises an antimicrobial preservative such as benzyl alcohol preferably at a concentration of about 0.001% to about 5.0% w/w of the composition.
In yet another embodiment of the present invention, the composition additionally comprises a conventionally known antioxidant selected from but not limited to a group comprising ascorbyl palmitate, butyl hydroxy anisole, butyl hydroxy toluene, propyl gal late, α-tocopherol and the like, or mixtures thereof.
The compositions of the present invention are highly stable. In an embodiment, the novel compositions of the present invention may be diluted with suitable diluting fluids known to the art to prepare a solution or 'dispersion or infusion before administration. The novel compositions of the present invention are highly stable and compatible with different diluting fluids such as demineralized (DM) water, dextrose 5% w/v, sodium chloride 0.9% w/v or mixtures thereof. These fluids can be employed during the manufacture of the composition or can be used for diluting the composition before administration. For example, the composition is stable for 5 hrs upto 1 : 150 dilution and for 48 hrs up to 1 :5 dilution with DM water; for 2 hrs upto 1 : 150 dilution and for 4 hrs upto 1 :3 dilution with dextrose 5.0% solution; and for 24 hrs upto 1 : 150 dilution and for 48 hrs upto 1 : 100 dilution with 0.9% NaCl solution, particularly at room temperature.
The compositions of the present invention are preferably filled into ampoules. Compatibility study on nimesulide injection (content of one ampoule) with different infusion solutions were performed to study the physical stability (during intravenous infusion) of the injection after diluting with infusion solutions. Most of the infusion solutions possess pH in acidic range (e.g. Normal saline, about 6.2; Ringer lactate solution, about 6.5 and Dextrose 5% w/v, about 5.5). Admixing with infusion solution for known injections comprising a COX-II inhibitor or NSAID or COX/LOX inhibitor results into saturation and thus crystallization. This is not desirable for a solution if diluted as such since such solution is meant for parenteral administration. Thus, particularly in case of nimesulide as the active ingredient, it is required to maintain the pH of final solution at alkaline side to stabilize the nimesulide in infusion solution. Hence, compatibility studies were performed on the Nimesulide in infusion solutions already buffered with sodium bicarbonate to impart the alkalinity to the final solution and thus prevent recrystallization. The study showed that the injectable composition was highly stable and compatible with different infusion solutions.
In a further embodiment, ethanol and/or dimethylacetamide (DMA) can also be added to the compositions of the present invention to further enhance the solubility of the active ingredient(s).
Stability study was conducted on the composition stated in Example- 1 herein. Long term (at controlled room temperature i.e. 25°C), intermediate (at 300C and 70% RH), accelerated (at 400C and 75% RH), and stress (at 600C) stability studies were performed on the product and samples were analyzed including the controlled samples kept at freezing conditions (at 2-80C). The product was found to be stable for more than six months at each of the above conditions and it did not show any stability issues relating to physical changes like particulate matter, crystallization and color change or chemical changes such as change in potency or presence of any degradation product.
Furthermore, in order to assess the product stability, 'freeze-thaw cycle' study was also conducted and the product was found to be stable physically and chemically even after four freeze-thaw cycles (i.e. refrigeration of the product followed by keeping the product at 400C and 75% RH for one day each).
In the present invention, the nimesulide injection is formulated preferably as an aqueous injection meant for dilution with infusion solutions particularly in case of IV administration. Nimesulide possess pH dependent solubility i.e. nimesulide is soluble at alkaline pH and practically insoluble at acidic pH. Thus, preferably a solvent system comprising a mixture of solvents (particularly glycols) optionally along with a pH adjusting system has been adopted to prepare a stable formulation in the present invention.
Pharmacological Study
Acute toxicity study of nimesulide IV injection was carried in female Swiss mice weighing between 20-25 g (n = 6 per group). The samples used for the study were Nimesulide IV injection (Label claim: Each 3 ml contains 100 mg of nimesulide) and Placebo injection. 0.1 ml of injection equivalent to doses of 41.6, 50, 54.17, 58.3 and 83.3 mg of nimesulide per kg body weight were administered by IV route for 14 days. Mice injected with 0.1 ml of injection equivalent to a dose of 50.0 mg/kg, 54.17 mg/kg, and 83.3 mg/kg showed toxic symptoms of decreased locomotor activity, stupor, and tremors. Mice injected at dose level of 41.6 mg/kg and 5 ml/kg placebo did not show any toxic symptom. The mortality rate of 16.6 %, 50 %, and 100% was observed at dose levels of 54.17 mg/kg, 58.3 mg/kg, and 83.3 mg/kg respectively. The LD5O of the nimesulide injection (IV) was found to be 57.54 mg/kg.
Acute toxicity study of nimesulide IM injection was carried out in female Swiss mice weighing between 20-25 g (n = 5 per group). The samples used for the study were
Nimesulide IM injection (Label claim: Each 3 ml contains 100 mg of nimesulide) and
Placebo injection. The dose given was 1.25, 2.5, 5, 6.25, and 7.5 ml/kg of Nimesulide
IM injection equivalent to 41.6, 83.3, 166.67, 208.33, and 250 mg of nimesulide per kg body weight respectively by IM route for 14 days. No toxicity symptoms were observed at dose level of 41.6 mg/kg of nimesulide injection and with 2.5 ml/kg placebo injection in mice. Mice injected with a dose of 83.3, 166.67, 208.33 or 250 mg/kg showed toxicity symptoms. The" mortality rates of 40%, 80%, and 100% were observed at dose level of 166.67 mg/kg, 208.33 mg/kg, and 250 mg/kg respectively. The LD50 of the nimesulide injection when administered intramuscularly was found to be 173.78 mg/kg.
A study was conducted to compare the hemolytic potential of Nimesulide IV injection 100 mg/ml of the present invention with that of commercially available IV/IM injections on Rat whole blood (citrated) and Rat packed red blood cells (citrated). The commercially available IV/IM injections used for the study were Diazepam injection 5 mg/ml (CALMPOSE®), Diclofenac sodium injection 25 mg/ml (VOVERAN®), Frusemide injection 10 mg/ml (LASIX®), Nimesulide injection 10% w/v (NIMOVET®), and Pentazocin lactate injection 30 mg/ml (FORTWIN®). The study showed that Nimesulide IV injection of the present invention when tested (at blood to test sample ratio of 1 : 10) on Rat packed red blood cells (citrated) showed comparative fractions of healthy cells as compared to CALMPOSE®, FORTWIN®, NIMOVET® and VOVERAN®. Nimesulide IV injection when tested (at blood to test sample ratio of 13: 1) on Rat whole blood (citrated) showed comparative fractions of healthy cells as compared to CALMPOSE®, FORTWIN®, and LASIX®.
The perivenous tolerance following a single intravenous administration of Nimesulide IV injection 100 mg/3 ml of the present invention against a placebo composition was studied in rabbits. The study showed that the animals injected intravenously with Nimesulide IV injection of the present invention or the placebo did not show any signs of local irritation at the site of injection in the right ears.
Pharmacokinetic study of Nimesulide IV injection of the present invention was carried out in rabbits. Albino rabbits (1.9-2.1 kg) of either sex (n=4 rabbits) were selected for the study. Nimesulide IV injection, each 2 ml ampoule containing 75 mg nimesulide, was used. A dose of 3.75 mg/kg body weight of rabbit equivalent to human dose of 75 mg/60kg were administered by IV route, via marginal ear vein of rabbits and blood sampling was done at 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hour intervals, and the plasma samples were analyzed for nimesulide by LC-MS/MS. The pharmacokinetic profile of Nimesulide injection in rabbits is presented below: Table-l: Pharmacokinetic profile of Nimesulide injection in rabbits
S. No. Time (in hours) Average Plasma concentration of Nimesulide (microgram/ml)
1 0 0.00 2 0.25 17.00
3 0.5 15.90
4 1 13.35
5 1.5 10.73
6 2 8.57 7 2.5 8.18
8 3 7.83
9 4 6.26
10 6 3.10 1 1 8 1.41
12 10 0.62
13 12 0.24
14 24 0.00
In a further embodiment of the present invention, a process for the preparation of such novel injectable compositions is provided.
In an embodiment, the process for preparation of a novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system comprising a mixture of glycols; optionally with other pharmaceutically acceptable excipients, which comprises of the following steps: i) adding the active ingredient(s) to the mixture of glycols followed by mixing, ii) optionally adding other pharmaceutically acceptable excipients and mixing to produce the injectable composition.
In another embodiment, the process for preparation of a novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor and/or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system comprising a mixture of glycols; optionally with other pharmaceutically acceptable excipients, additionally comprising one or more buffering agent(s) and/or alkalizing agent(s), which comprises of the following steps: i) adding one or more buffering agent(s) to the mixture of glycols and mixing to obtain a homogeneous mixture, ii) adding the active ingredient(s) to the mixture followed by mixing, iii) adding alkalizing agent(s) followed by mixing, iv) adding the buffering agent(s) with mixing to obtain a homogeneous mixture, v) optionally adjusting the pH of the mixture to an alkaline pH by adding alkalizing agent(s) to produce the injectable composition.
In another embodiment, the process as described herein comprises the active ingredient selected from a group comprising of at least one COX-II inhibitor or NSAID or
COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof, optionally with one or more additional active ingredient(s) that can be combined with a COX-II inhibitor or NSAID known to art. Preferably the
NSAID is nimesulide or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof.
In yet another embodiment of the present invention, therapeutic methods of use of such compositions are provided. The analgesic and anti-inflammatory injectable compositions of the present invention are useful for the treatment of acute painful conditions like post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurological pain and pain associated with sciatica and spondylitis, and the like, in mammals particularly in humans and animals, more particularly in humans.
In a further embodiment, the present invention provides a method of using the novel injectable pharmaceutical composition, which comprises administering to a patient in need thereof an effective amount of the composition.
In a further embodiment, the present invention provides a method of using the injectable pharmaceutical composition preferably for the treatment of acute and/or chronic painful conditions in mammals particularly mammals, including a variety of painful and inflammatory conditions like postoperative pain, primary dysmenorrhea and painful osteoarthritisand/or other associated disorders such as inflammation, fever, allergy, or the like.
In a further embodiment, the present invention provides a method of using the injectable pharmaceutical composition particularly for the treatment of acute painful conditions, wherein such condition is one or more of post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurological pain and pain associated with sciatica and spondylitis. In a further embodiment is provided the use of the compositions of the present invention for the preparation of medicament for the treatment of acute painful conditions, wherein such condition is one or more of post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurological pain and pain associated with sciatica and spondylitis, and/or chronic painful conditions, and/or painful and inflammatory conditions like postoperative pain, primary dysmenorrhea and painful osteoarthritis and/or other associated disorders such as inflammation, fever, allergy, or the like. Some typical examples illustrating embodiments of the present invention are provided. However, it should also be understood that the particular compositions, processes and methods illustrating the present invention are exemplary only and should not be regarded as limitations of the present invention.
EXAMPLES
Example-1: Nimesulide Injection (100 mg/3 ml)
S. No. Ingredients Quantity/ 100 ml
1. Polyethylene glycol (PEG-400) 30.00 ml
2. Propylene Glycol 20.00 ml 3. Glycine Buffer pH 1 1.3 36.00 ml
4. Nimesulide 3.34 gm
5. Sodium hydroxide (NaOH) solution 4.0% w/v 1 1.20 ml Procedure: i) Take specified quantity (30.00 ml) of PEG-400 into a vessel. ii) Add Propylene glycol (20.00 ml) to step (i) with continuous stirring using mechanical stirrer, iii) Add about 30.0 ml of the Glycine Buffer pH 1 1.3 to the step (ii) with continuous stirring to form a homogeneous mixture. iv) Add weighed amount of Nimesulide (3.34 gm) passed through #60 mesh to the step (iii) with continuous stirring. v) Add specified quantity (1 1.20 ml) of NaOH 4.0% solution to the step (iv) with continuous stirring to form a homogeneous solution, vi) Mix the solution for about 30 minutes by continuous stirring, vii) Add remaining quantity of Glycine Buffer pH 1 1.3 to make up the volume to 100 ml. viii) Mix the solution for about 10 minutes by continuous stirring, ix) Adjust final pH to 10.0 by adding NaOH 4.0% w/v solution, x) Mix the solution for about 10 minutes by continuous stirring.
Example-2: Diclofenac Injection (75 mg/3 ml)
S. No. Ingredients Quantity/ 100 ml
1. Polyethylene glycol (PEG-300) 30.00 ml
2. Propylene Glycol 20.00 ml
3. Glycine Buffer pH 12.0 30.00 ml 4. Diclofenac 2.50 gm
5. Sodium hydroxide (NaOH) solution 4.0% w/v 10.00 ml
Procedure: i) Take specified quantity (30.00 ml) of PEG-300 into a vessel, ii) Add Propylene glycol (20.00 ml) to step (i) with continuous stirring. iii) Add about 25.0 ml of the Glycine Buffer pH 12.0 to the step (ii) with continuous stirring to form a homogeneous mixture. iv) Add weighed amount of Diclofenac passed through #60 mesh to step (iii). v) Add specified quantity (10.00 ml) of NaOH 4.0% solution to the step (iv) with continuous stirring to form a homogeneous solution. vi) Mix the solution for about 30 minutes by continuous stirring, vii) Add remaining quantity of Glycine Buffer to step (vi). viii) Mix the solution for about 10 minutes by continuous stirring, ix) Adjust final pH to 7.5 by adding NaOH 4.0% w/v solution, x) Mix the solution for about 10 minutes by continuous stirring.
ExampIe-3: Indomethacin Injection (25 mg/3 ml)
S. No. Ingredients Quantity/ 100 ml
1. Polyethylene glycol (PEG-400) ' ' 30.00 ml
2. Propylene Glycol 20.00 ml 3. Lysine Buffer pH 10 42.00 ml
4. Indomethacin 0.84 gm
5. Sodium hydroxide (NaOH) solution 4.0% w/v 1 1.20 ml Procedure: i) Take specified quantity (30.00 ml) of PEG-400 into a vessel. ii) Add Propylene glycol (20.00 ml) to step (i) with continuous stirring, iii) Add about 36.0 ml of the Lysine Buffer to the step (ii) with continuous stirring, iv) Add weighed amount of Indomethacin passed through #60 mesh to step (iii). v) Add specified quantity (1 1.20 ml) of NaOH 4.0% solution to the step (iv) with continuous stirring to form a homogeneous solution. vi) Mix the solution for about 30 minutes by continuous stirring, vii) Add remaining quantity of Lysine Buffer to step (vi). viii) Mix the solution for about 10 minutes by continuous stirring, ix) Adjust final pH to 1 1.5 by adding NaOH 4.0% w/v solution. x) Mix the solution for about 10 minutes by continuous stirring.
ExampIe-4: Rofecoxib Injection (25 mg/3 ml)
S. No. Ingredients Quantity/ 100 ml
1. Polyethylene glycol (PEG-400) 20.00 ml 2. Propylene Glycol 20.00 ml
3. Dimethylacetamide 10.00 ml
4. Glycine Buffer pH 1 1.3 36.00 ml
5. Rofecoxib . 0.84 gm
6. Sodium hydroxide (NaOH) solution 4.0% w/v 12.00 ml Procedure i) Take specified quantity (20.00 ml) of PEG-400 into a vessel. ii) Add Propylene glycol (20.00 ml) to step (i) with continuous stirring using mechanical stirrer. Add 10.00 ml of Dimethylacetamide and mix. iii) Add about 30.0 ml of the Glycine Buffer pH 1 1.3 to step (ii). iv) Add weighed amount of Rofecoxib passed through #60 mesh to step (iii). v) Add specified quantity (12.00 ml) of NaOH 4.0% solution to the step (iv) with continuous stirring to form a homogeneous solution. vi) Mix the solution for about 30 minutes by continuous stirring. vii) Add remaining quantity of Glycine Buffer pH 1 1.3 to make up the volume to 100 ml. viii) Mix the solution for about 10 minutes by continuous stirring. ix) Adjust final pH to 1 1.0 by adding NaOH 4.0% w/v solution. x) Mix the solution for about 10 minutes by continuous stirring. Example-5: Licofelone Injection (100 mg/3 ml)
S. No. Ingredients Quantity/ 100 ml
1. Polyethylene glycol (PEG-400) 30.00 ml
2. Propylene Glycol 20.00 ml 3. Glycine Buffer pH 1 1.3 36.00 ml
4. Licofelone 3.34 gm
5. Sodium hydroxide (NaOH) solution 3.0% w/v 14.40 ml Procedure i) Take specified quantity (30.00 ml) of PEG-400 into a vessel. H) Add Propylene glycol (20.00 ml) to step (i) with continuous stirring. iii) Add about 30.0 ml of the Glycine Buffer pH 1 1.3 to the step (ii) with continuous stirring to form a homogeneous mixture. iv) Add weighed amount of licofelone' passed through #60 mesh to step (iii). v) Add specified quantity (14.40 ml) of NaOH 3.0% solution to the step (iv) with continuous stirring to form a homogeneous solution. vi) Mix the solution for about 30 minutes by continuous stirring. vii) Add remaining quantity of Glycine Buffer pH 1 1.3 to make up the volume to 100 ml. viii) Mix the solution for about 10 minutes by continuous stirring. ix) Adjust final pH to 10.0 by adding NaOH 3.0% w/v solution. x) Mix the solution for about 10 minutes by continuous stirring.
ExampIe-6: Nimesulide Injection (100 mg/3 ml)
S. No. Ingredients Quantity/ 100 ml
1. Polyethylene glycol (PEG-400) . 30.00 ml 2. Propylene Glycol 20.00 ml
3. Glycine Buffer pH 11.3 36.00 ml
4. Nimesulide micronized 3.34 gm
5. Sodium hydroxide (NaOH) solution 5.0% w/v 1 1.00 ml Procedure i) Take specified quantity (30.00 ml) of PEG-400 into a vessel. ii) Add Propylene glycol (20.00 ml) to step (i) with continuous stirring, iii) Add about 30.0 ml of the Glycine Buffer pH 1 1.3 to the step (ii) with continuous stirring to form a homogeneous mixture. iv) Add weighed amount of Nimesulide micronized passed through #60 mesh to the step (iii) with continuous stirring, v) Add specified quantity (1 1.00 ml) of NaOH 5.0% solution to the step (iv) with continuous stirring to form a homogeneous solution. vi) Mix the solution for about 30 minutes by continuous stirring. vii) Add remaining quantity of Glycine Buffer pH 1 1.3 to make up the volume to 100 ml. viii) Mix the solution for about 10 minutes by continuous stirring, ix) Adjust final pH to 10.0 by adding NaOH 5.0% w/v solution, x) Mix the solution for about 10 minutes by continuous stirring.
ExampIe-7: Nimesulide Injection (100 mg/3 ml)
S. No. Ingredients Quantity/ 100 ml
1. Polyethylene glycol (PEG-400) 30.00 ml
2. Propylene Glycol 20.00 ml 3. Glycine Buffer pH 1 1.3 36.00 ml
4. Nimesulide 3.34 gm
5. Potassium hydroxide (KOH) solution 5.6 % w/v 1 1.00 ml Procedure i) Take specified quantity (30.00 ml) of PEG-400 into a vessel. ii) Add Propylene glycol (20.00 ml) to step (i) with continuous stirring. iii) Add about 30.0 ml of the Glycine Buffer pH 1 1.3 to the step (ii) with continuous stirring to form a homogeneous mixture, iv) Add weighed amount of Nimesulide (3.34 gm) passed through #60 mesh to the step (iii) with continuous stirring. v) Add specified quantity (1 1.00 ml) of KOH 5.6% solution to the step (iv) with continuous stirring to form a homogeneous solution, vi) Mix the solution for about 30 minutes by continuous stirring, vii) Add remaining quantity of Glycine Buffer pH 1 1.3 to make up the volume to 100 ml. viii) Mix the solution for about 10 minutes by continuous stirring. ix) Adjust final pH to 1 1.0 by adding KOH 5.6% w/v solution, x) Mix the solution for about 10 minutes by continuous stirring. Example-8: Nimesulide Injection (100 mg/3 ml)
S. No. Ingredients Quantity/ 100 ml
1. Polyethylene glycol (PEG-400) 30.00 ml
2. Propylene Glycol 10.00 ml 3. Glycine Buffer pH 1 1.3 46.00 ml
4. Nimesulide 3.34 gm
5. Potassium hydroxide (KOH) solution 4.0 % w/v 13.80 ml Procedure i) Take specified quantity (30.00 ml) of PEG-400 into a vessel. ii) Add Propylene glycol (10.00 ml) to step (i) with continuous stirring. iii) Add about 40.0 ml of the Glycine Buffer pH 1 1.3 to the step (ii) with continuous stirring to form a homogeneous mixture, iv) Add weighed amount of Nimesulide (3.34 gm) passed through #60 mesh to the step (iii) with continuous stirring. v) Add specified quantity (13.80 ml) of KOH 4.0% solution to the step (iv) with continuous stirring to form a homogeneous solution, vi) Mix the solution for about 30 minutes by continuous stirring, vii) Add remaining quantity of Glycine Buffer pH 11.3 to make up the volume to 100 ml. viii) Mix the solution for about 10 minutes by continuous stirring. ix) Adjust final pH to 1 1.0 by adding KOH 4.0% w/v solution, x) Mix the solution for about 10 minutes by continuous stirring.
Example-9: Nimesulide Injection (100 mg/3 ml)
S. No. Ingredients Quantity/ 100 ml 1. Polyethylene glycol (PEG-600) 20.00 ml
2. Propylene Glycol 10.00 ml
3. Phosphate Buffer pH 7.2 "' 56.00 ml
4. Nimesulide 3.34 gm 5: Potassium hydroxide (KOH) solution 5.6 % w/v 1 1 .20 ml Procedure i) Take specified quantity (20.00 ml) of PEG-600 into a vessel. iJX Add Propylene glycol (10.00 ml) to step (i) with continuous stirring. iii) Add about 50.0 ml of the Phosphate Buffer pH 7.2 to the step (ii) with continuous stirring to form a homogeneous mixture, iv) Add weighed amount of Nimesulide (3.34 gm) passed through #60 mesh to the step (iii) with continuous stirring. v) Add specified quantity (1 1.20 ml) of KOH 4.0% solution to the step (iv) with continuous stirring to form a homogeneous solution, vi) Mix the solution for about 30 minutes by continuous stirring, vii) Add remaining quantity of Phosphate Buffer pH 7.2 to make up volume to 100 ml. viii) Mix the solution for about 10 minutes by continuous stirring. ix) Adjust final pH to 1 1.0 by adding KOH 5.6% w/v solution, x) Mix the solution for about 10 minutes by continuous stirring.
Example-10: Nimesulide Injection (100 mg/3 ml)
S. No. Ingredients ' Quantity/ 100 ml 1. Polyethylene glycol (PEG-300) 30.00 ml
2. Glycine Buffer pH 1 1.3 56.00 ml
3. Nimesulide micronized 3.34 gm
4. Potassium hydroxide (KOH) solution 6.5 % w/v "- 9.50 ml Procedure i) Take specified quantity (30.00 ml) of PEG-300 into a vessel. ii) Add about 40.0 ml of the Glycine Buffer pH 1 1.3 to the step (i) with continuous stirring to form a homogeneous mixture, iii) Add weighed amount of Nimesulide micronized passed through #60 mesh to the step (ii) with continuous stirring. iv) Add specified quantity (9.50 ml) -of KOH 6.5% solution to the step (iii) with continuous stirring to form a homogeneous solution, v) Mix the solution for about 30 minutes by continuous stirring, vi) Add remaining quantity of Glycine Buffer pH 11.3 to make up the volume to 100 ml. vii) Mix the solution for about 10 minutes by continuous stirring. viii) Adjust final pH to 9.5 by adding KOH 6.5% w/v solution, ix) Mix the solution for about 10 minutes by continuous stirring. Example-11: Nimesulide injection (75mg/2ml):
S. No. Ingredients Quantity/ 100 ml
1. Nimesulide micronized 3.77 gm
2. Polyethylene Glycol (PEG 400) 30.00 ml 3. Propylene Glycol 20.00 ml
4. Glycine Buffer pH 1 1.3 35.00 ml
5. NaOH solution 4.0% ' 13.00 ml Procedure i) Take specified quantity (30.00 ml) of PEG-400 into a vessel. ii) Add Propylene glycol (20.00 ml) to step (i) with continuous stirring. iii) Add about 30.00 ml of the Glycine Buffer pH 1 1.3 to the step (ii) with continuous stirring to form a homogeneous mixture, iv) Add weighed amount of Nimesulide (3.75 g) passed through #60 mesh to the step (iii) with continuous stirring. v) Add specified quantity (13.00 ml) of NaOH 4.0% solution to the step (iv) with continuous stirring to form a homogeneous solution, vi) Mix the solution for about 30 minutes by continuous stirring, vii) Add remaining quantity of Glycine Buffer pH 1 1.3 to make up the volume to 100 ml. viii) Mix the solution for about 10 minutes by continuous stirring. ix) Adjust Final pH to 10.0 by adding NaOH 4.0% w/v solution, x) Mix the solution for about 10 minutes by continuous stirring.
Example-12: Licofelone injection (100 mg/3 ml):
S. No. Ingredients Quantity/ 100 ml 1. Licofelone 3.34 g
2. Polyethylene Glycol (PEG-400) 30.00 ml
3. Propylene Glycol 20.00 ml
4. Glycine Buffer pH 1 1.3 30.00 ml
5. NaOH solution 4.0% . 15.00 ml Procedure i) Take specified quantity (30.00 ml) of PEG-400 into a vessel, ii) Add Propylene glycol (20.00 ml) to step (i) with continuous stirring using mechanical stirrer. iii) Add about 28.00 ml of the Glycine Buffer pH 1 1.3 to the step (ii) with continuous stirring to form a homogeneous mixture, iv) Add weighed amount of Licofelone (3.34 g) passed through #60 mesh to the step (iii) with continuous stirring. v) Add specified quantity (15.00 ml) of NaOH 4.0% solution to the step (iv) with continuous stirring to form a homogeneous solution, vi) Mix the solution for about 30 minutes by continuous stirring, vii) Add remaining quantity of Glycine Buffer pH 1 1.3 to make up the volume to 100 ml. viii) Mix the solution for about 10 minutes by continuous stirring. ix) Adjust final pH to 10.0 by adding NaOH 4.0% w/v solution, x) Mix the solution for about 10 minutes by continuous stirring.
Example-13: Parecoxib injection (50 mg/2 ml):
S. No. Ingredients Quantity/ 100 ml 1. Parecoxib 2.50 g
2. Polyethylene Glycol (PEG-400) 30.00 ml
3. Propylene Glycol 20.00 ml
4. Glycine Buffer pH 1 1.3 34.00 ml
5. NaOH solution 4.0% 14.00 ml Procedure i) Take specified quantity (30.00 ml) of PEG-400 into a vessel. ii) Add Propylene glycol (20.00 ml) to step (i) with continuous stirring using mechanical stirrer. iii) Add about 30.00 ml of the Glycine Buffer pH 1 1.3 to the step (ii) with continuous stirring to form a homogeneous mixture. iv) Add weighed amount of Parecoxib (2.50 g) passed through #60 mesh to the step
(iii) with continuous stirring, v) Add specified quantity (14.00 ml) of NaOH 4.0% solution to the step (iv) with continuous stirring to form a homogeneous solution. vi) Mix the solution for about 30 minutes by continuous stirring. vii) Add remaining quantity of Glycine Buffer pH 1 1.3 to make up the volume to 100 ml. viii) Mix the solution for about 10 minutes by continuous stirring, ix) Adjust final pH to 10.0 by adding NaOH 4.0% w/v solution. x) Mix the solution for about 10 minutes by continuous stirring.
Example-14: Diclofenac Sodium injection (75 nig/2 ml):
S. No. Ingredients Quantity/ 100 nil 1. Diclofenac Sodium 3.77 g
2. Polyethylene Glycol (PEG-400) 30.00 ml
3. Propylene Glycol 20.00 ml
4. Glycine Buffer pH 11.3 35.00 ml
5. NaOH solution 4.0% 13.00 ml Procedure i) Take specified quantity (30.00 ml) of PEG-400 into a vessel. ii) Add Propylene glycol (20.00 ml) to step (i) with continuous stirring using mechanical stirrer. iii) Add about 30:00 ml of the Glycine Buffer pH 1 1.3 to the step (ii) with continuous stirring to form a homogeneous mixture. iv) Add weighed amount of Diclofenac sodium (3.77 g) passed through #60 mesh to the step (iii) with continuous stirring, v) Add specified quantity (13.00 ml) of NaOH 4.0% solution to the step (iv) with continuous stirring to form a homogeneous solution. vi) Mix the solution for about 30 minutes by continuous stirring. vii) Add remaining quantity of Glycine Buffer pH 1 1.3 to make up the volume to 100 ml. viii) Mix the solution for about 10 minutes by continuous stirring, ix) Adjust final pH to 10.0 by adding NaOH 4.0% w/v solution, x) Mix the solution for about 10 minutes by continuous stirring.
Example-15: Ibuprofen injection (200 mg/2 ml):
S. No. Ingredients Quantity/ 100 ml
1. Ibuprofen 10 g
2. Polyethylene Glycol (PEG-400) 30.00 ml 3. Propylene Glycol 20.00 ml
4. Glycine Buffer pH 1 1.3 25.00 ml
5. NaOH solution 4.0% 18.00 ml Procedure i) Take specified quantity (30.00 ml) of PEG-400 into a vessel. ii) Add Propylene glycol (20.00 ml) to step (i) with continuous stirring. iii) Add about 22.00 ml of the Glycine Buffer pH 1 1.3 to the step (ii) with continuous stirring to form a homogeneous mixture. iv) Add weighed amount of Ibuprofen (10.00 g) passed through #60 mesh to the step (iii) with continuous stirring. v) Add specified quantity (18.00 ml) of NaOH 4.0% solution to the step (iv) with continuous stirring to form a homogeneous solution, vi) Mix the solution for about 30 minutes by continuous stirring, vii) Add remaining quantity of Glycine Buffer pH 1 1.3 to make up the volume to 100 ml. viii) Mix the solution for about 10 minutes by continuous stirring, ix) Adjust final pH to 10.0 by adding NaOH 4.0% w/v solution, x) Mix the solution for about 10 minutes by continuous stirring.

Claims

1. A novel injectable pharmaceutical composition comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor or its tautomeric forms, or its analogues, isomers, polymorphs, solvates, prodrugs, or salts or thereof as active ingredient from 0.1% to 80% w/v and a solvent system comprising a mixture of glycols from 1% to 80% v/v; optionally with other pharmaceutically acceptable excipients.
2. A composition according to claim 1 , wherein the said composition additionally comprises at least one alkalizing agent from 0.2% to 60% v/v.
3. A composition according to claim 1, wherein the said composition comprises at least one buffering agent from 2% to 80% v/v.
4. A composition according to claims 1 to 3, wherein the COX-II inhibitor is selected from a group comprising celecoxib, rofecoxib, valdecoxib, etoricoxib, parecoxib, itacoxib, deracoxib or their tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs or salts thereof.
5'. A composition according to claims 1 to 3, wherein the NSAID is selected from a group comprising nimesulide, nabumetone, tapoxalin, diclofenac, flosulide, ibuprofen, indomethacin, naproxen or their tautomeric forms, analogues, . isomers, polymorphs, solvates, prodrugs, or salts thereof.
6. A composition according to claim 5, wherein the NSAID is nimesulide or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof.
7. A composition according to claim 1 , wherein the COX/LOX inhibitor is licofelone.
8; A composition according to claims 1 to 7, wherein the active ingredient is in the micronized form.
9. A composition according to claim 1 , wherein the solvent system comprises a mixture of polyethylene glycol and propylene glycol.
10. A composition according to claim 9, wherein the polyethylene glycol (PEG) is selected from a group comprising PEG 200, PEG 300, PEG 400, PEG 600 and PEG 700, or mixtures thereof.
1 1. A composition according to claim 10, wherein the solvent system comprises a mixture of PEG 400 and propylene glycol.
12. A composition according to claim 2, wherein the alkalizing agent is selected from a group comprising inorganic bases and/or organic bases.
13. A composition according to claim 12, wherein the inorganic base is selected from a group comprising sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, calcium carbonate, magnesium carbonate and magnesium oxide, or mixtures thereof.
14. A composition according to claim 12, wherein the organic base is selected from a group comprising meglumine, triethanolamine and diethanolamine, or mixtures thereof.
15. A composition according to claim 3, wherein the buffering agent is an alkaline buffering agent.
16. A composition according to claim 15, wherein the alkaline buffering agent is selected from a group comprising glycine buffer, lysine buffer, phosphate buffer and acetate buffer, or mixtures thereof, having a pH of about 7.2 to about 12.5.
17. A composition according to claim 16, wherein the buffering agent is glycine buffer having a pH of about 8.3 to about 1 1.3.
18. A composition according to claim 1, wherein the pharmaceutical excipients are selected from a group comprising vehicles, bulking agents, stabilizers, preservatives, surfactants, hydrophilic polymers, solubility enhancing agents, tonicity adjusting agents, local anesthetics, pH adjusting agents, antioxidants, osmotic agents, chelating ' agents, viscosifying agents, wetting agents, emulsifying agents, acids, sugar alcohol, reducing sugars and non-reducing sugars, either alone or in combination thereof, used in an amount of about 0.1% to about 70% w/v or v/v of the composition.
19. A composition according to claim 18, wherein the solubility enhancing agent is selected from a group comprising glycerine, various grades of polyethylene oxides, beta-cyclodextrins, transcutol and glycofurol, or mixtures thereof.
20. A composition according to claim 18, wherein the vehicle is selected from a group comprising dimethylacetamide, dimethylformamide, dimethylsulphoxide, N-methyl pyrrolidone, benzyl benzoate, benzyl alcohol, ethyl oleate, polyoxyethylene glycolated castor oils, polyethylene glycol, propylene glycol, hexylene glycols, butylene glycols and glycol derivatives, or mixtures thereof.
21. A composition according to claims 1 to 20, which additionally comprises an antimicrobial preservative.
22. A composition according to claims 1 to 21, which additionally comprises an antioxidant.
23. A composition according to claim 22, wherein antioxidant is selected from a group comprising ascorbyl palmirate, butyl hydroxy anisole, butyl hydroxy toluene, propyl gallate and α-tocopherol, or mixtures thereof.
24. A composition according to claims 1 to 23, wherein ethanol and/or dimethylacetamide is added to further enhance the solubility of the active ingredient.
25. A composition according to claims 1 to 24, wherein the injectable compositions are suitable for parenteral administration by intravenous or intramuscular route.
26. A process for preparation of a novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system comprising a mixture of glycols; optionally with other pharmaceutically acceptable excipients, which comprises of the following steps: i) adding the active ingredient(s) to the mixture of glycols followed by mixing, ii) optionally adding other pharmaceutically acceptable excipients and mixing to produce the injectable composition.
27. A process for preparation of a novel injectable pharmaceutical compositions comprising at least one COX-II inhibitor or NSAID or COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof as active ingredient and a solvent system comprising a mixture of glycols; Optionally with other pharmaceutically acceptable excipients, additionally comprising one or more buffering agent(s) and/or alkalizing agent(s), which comprises of the following steps: i) adding one or more buffering agent(s) to the mixture of glycols and mixing to obtain a homogeneous mixture, ii) adding the active ingredient(s) to the mixture followed by mixing, iii) adding alkalizing agent(s) followed by mixing, iv) adding the buffering agent(s) with mixing to obtain a homogeneous mixture, v) optionally adjusting the pH of the mixture to an alkaline pH by adding alkalizing agent(s) to produce the injectable composition.
28. A process according to claims 26 or 27, wherein the active ingredient is selected from a group comprising of at least one COX-II inhibitor or NSAID or
COX/LOX inhibitor, or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof.
29. A process according to claim 28, wherein the NSAID is nimesulide or its tautomeric forms, analogues, isomers, polymorphs, solvates, prodrugs, or salts thereof.
30. A method of using the injectable pharmaceutical composition according to claim 1, which comprises administering to a patient in need thereof an effective amount of the composition.
3 1 . A method of using the injectable pharmaceutical composition according to claim 30, for the treatment of acute painful conditions, wherein such condition is one or more of post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurological pain and pain associated with sciatica and spondylitis, postoperative pain, primary dysmenorrhea, painful osteoarthritis, and/or other associated disorders such as inflammation, fever, or allergy.
32. Use of a composition according to claim 1 for the preparation of a medicament for the treatment of acute painful conditions, wherein such condition is one or more of post-operative trauma, pain associated with cancer, sports injuries, migraine headache, neurological -pain and pain associated with sciatica and spondylitis, postoperative pain, primary dysmenorrhea, painful osteoarthritis, and/or other associated disorders such as inflammation, fever, or allergy.
33. The pharmaceutical compositions substantially as herein described and illustrated by the examples.
34. The processes for the preparation of pharmaceutical compositions substantially as herein described and illustrated by the examples.
PCT/IN2006/000177 2005-05-27 2006-05-25 Injectable compositions and process for preparation of such compositions WO2006126214A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA002609242A CA2609242A1 (en) 2005-05-27 2006-05-25 Injectable compositions and process for preparation of such compositions
AU2006250765A AU2006250765A1 (en) 2005-05-27 2006-05-25 Injectable compositions and process for preparation of such compositions
EP06756263A EP1895983A2 (en) 2005-05-27 2006-05-25 Injectable compositions and process for preparation of such compositions
BRPI0611170-0A BRPI0611170A2 (en) 2005-05-27 2006-05-25 injectable compositions and process for preparing such compositions
JP2008513009A JP2008542260A (en) 2005-05-27 2006-05-25 Novel injectable composition and method for its preparation
RSP-2007/0461A RS20070461A (en) 2005-05-27 2006-05-25 Injectable compositions and process of preparation of such compositions
MX2007014862A MX2007014862A (en) 2005-05-27 2006-05-25 Injectable compositions and process for preparation of such compositions.
EA200702646A EA200702646A1 (en) 2005-05-27 2006-05-25 COMPOSITIONS FOR INJECTION AND METHOD FOR PREPARING THESE COMPOSITIONS
NO20076468A NO20076468L (en) 2005-05-27 2007-12-14 Injectable compositions and methods for preparing such compositions
TNP2007000482A TNSN07482A1 (en) 2005-05-27 2007-12-21 NOVEL INJECTABLE COMPOSITIONS AND PROCESS FOR THE PREPARATION OF SAID COMPOSITIONS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1357DE2005 2005-05-27
IN1357/DEL/2005 2005-05-27

Publications (2)

Publication Number Publication Date
WO2006126214A2 true WO2006126214A2 (en) 2006-11-30
WO2006126214A3 WO2006126214A3 (en) 2007-06-07

Family

ID=36917368

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2006/000177 WO2006126214A2 (en) 2005-05-27 2006-05-25 Injectable compositions and process for preparation of such compositions

Country Status (15)

Country Link
EP (1) EP1895983A2 (en)
JP (1) JP2008542260A (en)
KR (1) KR20080016689A (en)
CN (1) CN101217939A (en)
AU (1) AU2006250765A1 (en)
BR (1) BRPI0611170A2 (en)
CA (1) CA2609242A1 (en)
CR (1) CR9616A (en)
EA (1) EA200702646A1 (en)
MX (1) MX2007014862A (en)
NO (1) NO20076468L (en)
RS (1) RS20070461A (en)
TN (1) TNSN07482A1 (en)
WO (1) WO2006126214A2 (en)
ZA (1) ZA200711068B (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102512383A (en) * 2011-12-25 2012-06-27 天津市嵩锐医药科技有限公司 Parecoxib sodium pharmaceutical composition for injection
US8653137B2 (en) 2007-09-07 2014-02-18 United Therapeutics Corporation Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
WO2014102824A1 (en) * 2012-12-28 2014-07-03 Themis Medicare Limited Diclofenac composition
US9012508B2 (en) 2009-03-12 2015-04-21 Cumberland Pharmaceuticals Administration of intravenous ibuprofen
US9295639B2 (en) 2009-07-15 2016-03-29 Cumberland Pharmaceuticals Inc. Treating critically ill patients with intravenous ibuprofen
US9447065B2 (en) 2011-10-18 2016-09-20 Raqualia Pharma Inc. Pharmaceutical composition
US9447066B2 (en) 2012-12-28 2016-09-20 Askat Inc. Salts and crystal forms
WO2016170401A1 (en) * 2015-04-20 2016-10-27 Umedica Laboratories Pvt. Ltd Novel injectable composition of diclofenac sodium
US10369101B2 (en) 2013-03-15 2019-08-06 Latitude Pharmaceuticals Inc. Parenteral diclofenac composition
CN111103381A (en) * 2019-12-25 2020-05-05 南京希麦迪医药科技有限公司 Method for determining nimesulide concentration in human plasma by liquid chromatography-mass spectrometry
CN111741745A (en) * 2018-02-16 2020-10-02 威隆股份公司 Multipurpose torasemide composition
US11806400B2 (en) 2012-03-16 2023-11-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102335114B (en) * 2010-07-23 2015-07-15 重庆医药工业研究院有限责任公司 Stable ibuprofen arginine injection and preparation method thereof
CN102370615B (en) * 2010-08-19 2013-09-04 四川科伦药物研究有限公司 Ibuprofen injection preparation and preparation method thereof
CN103372216B (en) * 2012-04-26 2015-05-06 北京京卫燕康药物研究所有限公司 Solid medical composition containing celecoxib
CN103263385B (en) * 2013-05-17 2016-04-27 江苏正大清江制药有限公司 A kind of celecoxib long-acing nano injection and preparation method thereof
MA40599A1 (en) * 2014-12-20 2017-11-30 Troikaa Pharmaceuticals Ltd Injectable Formulations of Paracetamol
CN107303266B (en) * 2016-04-18 2020-09-08 重庆润泽医药有限公司 Levo-oxiracetam injection and preparation method thereof
CN107303264A (en) * 2016-04-18 2017-10-31 重庆润泽医药有限公司 Non-foam levo-oxiracetam parenteral solution and preparation method thereof
CN109498852B (en) * 2018-12-29 2022-06-24 广州噢斯荣医药技术有限公司 Biodegradable material for treating orthopedic diseases and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0595766A1 (en) * 1992-10-22 1994-05-04 Ciba-Geigy Ag Parenteral solutions containing diclofenac salts
EP0795329A1 (en) * 1996-03-15 1997-09-17 PULITZER ITALIANA S.r.l. Parenterally injectable piroxicam solutions
US6451302B1 (en) * 1998-01-12 2002-09-17 Panacea Biotec Limited Parenteral water-miscible non-intensely colored injectable composition of non-steroidal anti-inflammatory drugs
US20030078266A1 (en) * 2001-04-03 2003-04-24 Kararli Tugrul T. Reconstitutable parenteral composition
WO2004014431A1 (en) * 2002-08-12 2004-02-19 Ranbaxy Laboratories Limited A parenteral dosage form of selective cox-2 inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0595766A1 (en) * 1992-10-22 1994-05-04 Ciba-Geigy Ag Parenteral solutions containing diclofenac salts
EP0795329A1 (en) * 1996-03-15 1997-09-17 PULITZER ITALIANA S.r.l. Parenterally injectable piroxicam solutions
US6451302B1 (en) * 1998-01-12 2002-09-17 Panacea Biotec Limited Parenteral water-miscible non-intensely colored injectable composition of non-steroidal anti-inflammatory drugs
US20030078266A1 (en) * 2001-04-03 2003-04-24 Kararli Tugrul T. Reconstitutable parenteral composition
WO2004014431A1 (en) * 2002-08-12 2004-02-19 Ranbaxy Laboratories Limited A parenteral dosage form of selective cox-2 inhibitors

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8653137B2 (en) 2007-09-07 2014-02-18 United Therapeutics Corporation Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
US8658694B2 (en) 2007-09-07 2014-02-25 United Therapeutics Corporation Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
EP2200650B1 (en) * 2007-09-07 2016-01-06 United Therapeutics Corporation Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
US9327031B2 (en) 2007-09-07 2016-05-03 United Therapeutics Corporation Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
US9012508B2 (en) 2009-03-12 2015-04-21 Cumberland Pharmaceuticals Administration of intravenous ibuprofen
US9649284B2 (en) 2009-07-15 2017-05-16 Cumberland Pharmaceuticals, Inc. Treating critically ill patients with intravenous ibuprofen
US9295639B2 (en) 2009-07-15 2016-03-29 Cumberland Pharmaceuticals Inc. Treating critically ill patients with intravenous ibuprofen
US9931311B2 (en) 2009-07-15 2018-04-03 Cumberland Pharmaceuticals Inc. Treating critically ill patients with intravenous ibuprofen
US9447065B2 (en) 2011-10-18 2016-09-20 Raqualia Pharma Inc. Pharmaceutical composition
CN102512383A (en) * 2011-12-25 2012-06-27 天津市嵩锐医药科技有限公司 Parecoxib sodium pharmaceutical composition for injection
US11806400B2 (en) 2012-03-16 2023-11-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
EA035079B1 (en) * 2012-12-28 2020-04-24 Темис Медикэр Лимитед Diclofenac composition
KR101730284B1 (en) 2012-12-28 2017-04-25 테미스 메디케어 리미티드 Diclofenac composition
US9447066B2 (en) 2012-12-28 2016-09-20 Askat Inc. Salts and crystal forms
WO2014102824A1 (en) * 2012-12-28 2014-07-03 Themis Medicare Limited Diclofenac composition
US10369101B2 (en) 2013-03-15 2019-08-06 Latitude Pharmaceuticals Inc. Parenteral diclofenac composition
WO2016170401A1 (en) * 2015-04-20 2016-10-27 Umedica Laboratories Pvt. Ltd Novel injectable composition of diclofenac sodium
CN111741745A (en) * 2018-02-16 2020-10-02 威隆股份公司 Multipurpose torasemide composition
CN111741745B (en) * 2018-02-16 2024-03-26 威隆股份公司 Multipurpose torsemide composition
CN111103381A (en) * 2019-12-25 2020-05-05 南京希麦迪医药科技有限公司 Method for determining nimesulide concentration in human plasma by liquid chromatography-mass spectrometry

Also Published As

Publication number Publication date
NO20076468L (en) 2008-02-27
MX2007014862A (en) 2008-02-21
CN101217939A (en) 2008-07-09
KR20080016689A (en) 2008-02-21
TNSN07482A1 (en) 2009-03-17
EA200702646A1 (en) 2008-06-30
EP1895983A2 (en) 2008-03-12
JP2008542260A (en) 2008-11-27
CA2609242A1 (en) 2006-11-30
CR9616A (en) 2008-10-30
AU2006250765A1 (en) 2006-11-30
ZA200711068B (en) 2009-03-25
WO2006126214A3 (en) 2007-06-07
RS20070461A (en) 2008-11-28
BRPI0611170A2 (en) 2010-08-17

Similar Documents

Publication Publication Date Title
EP1895983A2 (en) Injectable compositions and process for preparation of such compositions
EP0814787B1 (en) Oil in water emulsions containing propofol and disodium edetate
EP2938325B1 (en) Diclofenac composition
TW200403073A (en) Parenteral formulations
CN107810000B (en) Injectable pharmaceutical composition of leflunomide
KR101383941B1 (en) Stable pharmaceutical composition containing piroxicam or its pharmaceutical acceptable salt and hyaluronic acid and its pharmaceutical acceptable salt and their manufacturing method thereof
WO2011014541A1 (en) Stable formulations of azacitidine
CA2596031C (en) Injectable preparations of diclofenic and its pharmaceutically acceptable salts
US9427398B2 (en) Parenteral solutions containing metolazone
SK7262003A3 (en) Pharmaceutical dronedarone composition for parenteral administration
MXPA02009336A (en) Amiodarone-containing parenteral solution.
EP1002531A1 (en) A water-miscible composition of non-steroidal antiinflammatory drugs
JPH11302197A (en) Hyaluronic acid-stabilizing composition
JP3917820B2 (en) Ozagrel sodium-containing injection and method for stabilizing the same
US20130137769A1 (en) Injectable Preparations Of Diclofenac And Its Pharmaceutically Acceptable Salts
JPH05139955A (en) Stable instillation
EP4134083A1 (en) Pharmaceutical compositions of bortezomib
EP1508332A1 (en) Medicinal composition
KR20210101193A (en) Injectable formulation with enhanced stability containing ibuprofen and afginine
EP1228757B1 (en) Stable pharmaceutical solutions of nimesulide
EP1556022A1 (en) Aqueous 2,6-diisopropylphenol pharmaceutical compositions
US20150141518A1 (en) Water-miscible stable solution composition for pharmaceutically active ingredients that are poorly soluble in water and susceptible to chemical degradation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2609242

Country of ref document: CA

Ref document number: 563613

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/014862

Country of ref document: MX

Ref document number: P-2007/0461

Country of ref document: RS

Ref document number: 2008513009

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2006250765

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006756263

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: CR2007-009616

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 200702646

Country of ref document: EA

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 07136818

Country of ref document: CO

Ref document number: 1020077030585

Country of ref document: KR

Ref document number: KR

WWW Wipo information: withdrawn in national office

Ref document number: RU

WWE Wipo information: entry into national phase

Ref document number: 200680025093.7

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2006250765

Country of ref document: AU

Date of ref document: 20060525

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006250765

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006756263

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0611170

Country of ref document: BR

Kind code of ref document: A2